VIGILANT BIOSCIENCES, INC.
CORAL SPRINGS, FLORIDA

Vigilant Biosciences® Vigilant Biosciences® is dedicated to helping create a world where cancer doesn’t stand a fighting chance. Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Our point-of-care and lab-based solutions are simple, accurate and cost-effective – empowering healthcare practitioners to improve potential outcomes through earlier intervention. Vigilant Biosciences products are based on patented technology that detects specific protein markers clinically shown to be associated with early stage cancers, potentially even prior to visual or physical indicators. The Vigilant Biosciences product line currently includes the OncAlert™ Oral Cancer RAPID Test and OncAlert Oral Cancer LAB Test, both CE Marked and available in select markets outside the United States; and the OncAlert Labs OraMark™ Test, a laboratory-developed test available only through OncAlert Labs, a CLIA certified laboratory. Vigilant Biosciences was founded after I watched both my parents struggle to overcome battles with oral cancer. My dad, a 15-year Stage II survivor, eventually succumbed to the disease in 2015 from the long-term adverse side effects of therapeutic intervention. My mom, who does not fit a typical risk profile for oral cancer, is a 5+ year Stage IV survivor. Like so many people diagnosed with oral cancer, hers was not accurately found and appropriately addressed until it had progressed to a late stage. Ultimately, my mom endured aggressive surgery, chemotherapy, radiation, and then reconstruction and rehabilitation. While she is now cancer-free, she lives daily having to learn a new way of life, learning a new way to speak, to eat, and to interact socially – things most people take for granted everyday. Her struggle, in particular, fuels my passion to lead Vigilant Biosciences to do more and make a meaningful impact in the lives of so many who are at risk for cancer or living with the disease. With a proven track record of experience in healthcare diagnostics and oncology, the Vigilant Biosciences® leadership team is committed to transforming early cancer detection and improving outcomes. While his history with Vigilant Biosciences originally dates back to 2013 as an early consultant to the Company, Mr. Heap officially re-joined Vigilant in December of 2016 first as a Board member and then expanding his involvement to assume the role of CEO in summer of 2017 to lead the Company’s transition from a development organization to a successful commercial enterprise. Mr. Heap has held a number of senior management positions, over a 45-year career, both in the eye care industry as President of CIBA Vision’s global contact lense business, President of Bausch and Lomb’s global contact lens and lens care business, and in the surgical product industry as CEO of Regent Medical, a leading manufacturer of surgeon gloves. Additionally, he previously served as a Board member for Cholestech, a point-of-care diagnostic company for measuring cholesterol and related lipids, that was later acquired by Inverness (now Alere). Michael Donovan Ph.D., M.D. serves as the Chief Medical Officer of Vigilant Biosciences. Dr. Donovan is board-certified in anatomic and clinical pathology and pediatric pathology with extensive experience in designing and implementing clinical studies. He has spearheaded the utilization of multiplex tissue and fluid-based assays and coupled mathematical applications to produce clinically relevant diagnostic/predictive/prognostic outcome models for a variety of tumor types and disease states. Along with his clinical duties, Dr. Donovan also serves as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mt. Sinai, New York City, New York. Elizabeth Franzmann, M.D. serves as the Scientific Founder and Chief Scientific Officer of Vigilant Biosciences. Her innovative clinical research on selective salivary biomarkers for head and neck squamous cell carcinoma serves as the foundation for Vigilant Biosciences’ product line. Sally Bowden leads Vigilant Biosciences in the regulatory, operations and quality endeavors, bringing more than 20 years of experience in the quality and regulatory fields of medical devices, companion diagnostics, education and health care systems. She also serves as the General Manager for OncAlert Labs, Vigilant’s CLIA lab. She has served in executive positions as Vice President of Quality Systems and Process Improvement at Ventana Medical Systems and as Vice President of Quality and Regulatory Compliance at Roche Diagnostics Corporation. She has served as an Associate Professor for Purdue University School of Engineering and Technology where she developed the Quality Management Curriculum within the Mechanical Engineering Technology department. Sally is a graduate of Purdue University School of Engineering and has also achieved her MBA. Sally founded Samco & Associates, Inc. in 2009 to provide consulting for companies interested in developing quality systems that meet FDA and global requirements and re-engineer them for efficient, effective compliance in the medical device field for all classes. In addition, Sally has helped to pioneer the Companion Diagnostic process in collaboration with pharmaceutical and diagnostic firms while building strong relationships with the applicable regulatory agencies. Robert T. Hamilton serves as the company’s Chief Financial Officer and VP of Administration. Mr. Hamilton is a former Big-Four CPA with 20+ years of public company and venture-backed private portfolio company experience having worked with companies in e-commerce, health and fitness, technology and retail/wholesale industries. Prior to Vigilant Biosciences, Mr. Hamilton served as CFO of Bridgevine, Inc., a privately held and venture-backed e-commerce solution. Prior to that, he was the CFO of eDiets, Inc. (formerly NASDAQ- DIET), a leading provider of online weight loss solutions. Mr. Hamilton began his career as an auditor with Arthur Andersen, LLP in Boston. Progressing to audit manager, he serviced multinational SEC and non-public clients in the high technology, manufacturing, retail/wholesale distribution, and hospitality industries. Mr. Hamilton is a Certified Public Accountant and received his bachelor’s degree in Business Administration from Merrimack College.